Tesamorelin is a 3rd generation GHRH that consists of a 44 amino acid sequence. It is a stabilized synthetic peptide analogue of the hypothalamic peptide, Growth Hormone Releasing Hormone (GHRH). It was approved in 2010 by the FDA for the treatment of Lipodystrophy in HIV patients. It stimulates the synthesis and release of endogenous GH, with an increase in the level of insulin-like growth factor. The release GH then binds with the receptors present on various body organs and regulates the body composition. This regulation is mainly because of the combination of anabolic and lipolytic mechanisms. It has been found that the main mechanisms by which Tesamorelin reduces the body fat mass are the lipolysis followed by a reduction in triglycerides level.